Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis

FDA Grants Radezolid QIDP for BV Indication

Melinta Therapeutics, Inc., a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that its partner has commenced a new program for a topical formulation of radezolid, a second-generation oxazolidinone antibiotic discovered by Melinta scientists, in preparation for submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the treatment of patients with bacterial vaginosis. Radezolid is also being studied by Melinta’s partner in a Phase 2 clinical study for the treatment of mild-to-moderate acne vulgaris.